FDA approves high dose of Regeneron's eye treatment Eylea in quick bounceback from June rejection
The FDA OK’d a high-dose version of Regeneron’s eye disease injectable Eylea on Friday evening just two months after deficiencies at …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
